If you’re in the doctor’s office,
“10 digits” means to examine the toes or fingers. But if you’re in the business world, 10
digits carries a quite different connotation.
It’s 1 billion US dollars, the yardstick of ‘big’ where everything seems
relative to what else takes place around you.
Earlier this month, the Wall Street Journal announced an agreement where AbbVie (a large pharma company) will pay Halozyme (my biotech company, small but growing) $1.2 billion during the development and selling of a basket of up to 9 drug targets. The signing itself landed $23 million in ‘mail box money’ and created some buzz in the healthcare world.
Over the next 3 days, the Halozyme stock price rose over $2 which in effect made Halozyme enter the mid-size company range with a revised market cap of over $2.5 billion. So unlike my prior work at the world’s largest medical device company, this time when a big deal lands at a small company, the results can be staggering.
Which brings me to the new job. In February, I mentioned the change to the “possibility” journey – working for a company with less than 200 employees with molecules that treat cancer among other things. It’s a rewarding (and different!) experience to work in a growing environment where what you do can really push the impact needle. I suppose that’s been the secret in the sauce with my new job – creating impact by doubling the lives of pancreatic cancer patients while at the same time seeing my fingerprints on the company.
In the end, a lot of life is about having the courage to take chances, building a team to go at it together, and convincing the affected stakeholders to permit your shot. At this point, anything can happen; however, it’s exciting and I’m hanging for the ride with both hands – that’s 10 digits for the doctor minded readers!
K
Earlier this month, the Wall Street Journal announced an agreement where AbbVie (a large pharma company) will pay Halozyme (my biotech company, small but growing) $1.2 billion during the development and selling of a basket of up to 9 drug targets. The signing itself landed $23 million in ‘mail box money’ and created some buzz in the healthcare world.
Over the next 3 days, the Halozyme stock price rose over $2 which in effect made Halozyme enter the mid-size company range with a revised market cap of over $2.5 billion. So unlike my prior work at the world’s largest medical device company, this time when a big deal lands at a small company, the results can be staggering.
Which brings me to the new job. In February, I mentioned the change to the “possibility” journey – working for a company with less than 200 employees with molecules that treat cancer among other things. It’s a rewarding (and different!) experience to work in a growing environment where what you do can really push the impact needle. I suppose that’s been the secret in the sauce with my new job – creating impact by doubling the lives of pancreatic cancer patients while at the same time seeing my fingerprints on the company.
In the end, a lot of life is about having the courage to take chances, building a team to go at it together, and convincing the affected stakeholders to permit your shot. At this point, anything can happen; however, it’s exciting and I’m hanging for the ride with both hands – that’s 10 digits for the doctor minded readers!
K
1 comment:
What a job that is both exciting and challenging!!!!!
Post a Comment